Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis

Tang, Boxiong; Rahman, Mirza I.; Waters, Heidi C.; Callegari, Peter E.

doi:10.1016/s0149-2918(08)80063-x

Cited by 89 publications

(68 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demographic (age and gender distribution) and clinical characteristics of the final matched study sample were found to be consistent with those reported by other studies of patients with RA that were conducted using retrospective database analysis. 2,4,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] However, in contrast to other studies where the majority of participants were white, the present study had a majority Hispanic population (53.7%). 31,32,36,37 This was expected, since Hispanics have been reported to account for a significant proportion (≈ 40%) of the Texas population.…”

Section: Medication Effectiveness With the Use Of Tumor Necrosis Factmentioning

confidence: 92%

“…2,3 The direct medical cost related to RA management in the United States has been estimated to exceed $4 billion annually. 4 RA negatively impacts patients' health-related quality of life, causing significant joint pain, disability, and limited mobility. 3 It has also been associated with increased mortality, since it predisposes patients to increased risk for cardiovascular-related diseases, cancer, infections, and mental health conditions.…”

Section: What This Study Addsmentioning

confidence: 99%

“…2,31,33,36 Differences in adherence may be a function of the route and frequency of administration. 4 IFX is administered intravenously at the physician's office by a health care provider, while ETN and ADA are administered subcutaneously by the patient. IFX is infused at week 0, 2, and 6 and every 8 weeks thereafter, while ETN is given once weekly and ADA is administered once every other week.…”

Section: Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis

Oladapo

Barner²,

Lawson³

et al. 2014

JMCP

View full text Add to dashboard Cite

While their effectiveness has not been directly compared in a clinical trial, results from the majority of the indirect treatment comparisons suggest comparable efficacy and safety profiles. However, these TNF inhibitor agents differ in administration method and dosing flexibility, which may result in differences in medication use profiles (e.g., adherence, persistence, discontinuation, dose escalation, and switching to a new biologic rheumatoid arthritis drug) and effectiveness in clinical practice.

show abstract

Section: Medication Effectiveness With the Use Of Tumor Necrosis Factmentioning

confidence: 92%

Section: What This Study Addsmentioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis

Oladapo

Barner²,

Lawson³

et al. 2014

JMCP

View full text Add to dashboard Cite

show abstract

“…Conversely, we did not explicitly quantify the contribution of persistence and treatment gaps to the overall cost per treated patient in this analysis, and previous research suggests that higher persistence to infliximab may contribute to its higher costs as compared with etanercept and adalimumab. 32 More than half of the patients who received a TNF blocker during the study period were excluded from the analysis. Many expected to increase the relative cost of etanercept in the first year.…”

Section: Limitationsmentioning

confidence: 99%

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

Schabert¹,

Watson²,

Joseph³

et al. 2013

JMCP

View full text Add to dashboard Cite

BACKGROUND: Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab are approved for use in adults with any of these conditions, but predicting the annual costs of TNF-blocker treatment is complex due to differences in dosing schedules, treatment gaps, switching between TNF blockers, and dose escalation over time.

show abstract

“…The evidence obtained from clinical trials is promising for the reduction of disease progression (Toussirot;Wendling, 2004;Smolen et al, 2007). The remission of the disease is more likely when ABT is used in the early stages of RA (Tang et al, 2008); in this study, only two trials (Moreland et al, 2002;Westhovens et al, 2009a) included patients who were within less than three years of disease onset.…”

Section: Discussionmentioning

confidence: 96%

Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis

Venson

Wiens

Correr

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The objective is to provide an update on the clinical efficacy, safety and tolerability of the use of abatacept for treating rheumatoid arthritis. A systematic review (up to June 2011) followed by meta-analyses was performed. Randomized controlled clinical trials comparing abatacept at a dose of 10 mg/kg with a placebo, both with concomitant methotrexate, were used. Only high-or moderate-quality studies were included. The efficacy was evaluated based on changes in the ACR, DAS and HAQ; safety was assessed based on serious adverse events, serious infections, malignancies and deaths; tolerability was evaluated based on the withdrawals due to adverse events, serious adverse events and lack of efficacy. All these parameters were evaluated within one year of treatment. Nine studies met the inclusion criteria, comprising 4,219 patients. For all of the efficacy parameters, the abatacept group had better results than the placebo group, except in the case of HAQ improvement >0.3, which presented no statistically significant difference. None of the safety parameters presented a significant difference between the groups. The tolerability parameters were also similar between groups, with the exception of withdrawals due to lack of efficacy. For this criterion, the abatacept group presented favorably compared to the control group. Abatacept showed a higher efficacy compared to placebo without significant differences between the abatacept and control group in terms of safety.Uniterms: Abatacept/efficacy. Rheumatoid arthritis/treatment. Meta-analyses.O objetivo foi fornecer dados atualizados sobre eficácia clínica, segurança e tolerabilidade do uso de abatacepte para o tratamento da artrite reumatoide. Realizaram-se uma revisão sistemática (com dados até junho/2011) e metanálises. Somente estudos clínicos controlados randomizados comparando o abatacepte (10 mg/kg) com placebo, ambos com uso concomitante de metotrexato, foram incluídos; todos possuíam qualidade alta ou moderada. A eficácia foi avaliada baseando-se em mudanças no ACR, DAS e HAQ; a segurança foi avaliada pelos eventos adversos e infecções graves, malignidades e mortes e a tolerabilidade pelo abandono do tratamento devido a eventos adversos (graves ou não) e falta de eficácia. Todos esses parâmetros foram avaliados ao final de um ano de tratamento. Nove estudos se adequaram aos critérios de inclusão, envolvendo 4219 pacientes. Em todos os parâmetros avaliados, o grupo tratado com abatacepte obteve melhores resultados, exceto para a melhora (>0,3) no HAQ (sem diferença estatisticamente significativa). Nenhum critério de segurança ou tolerabilidade apresentou diferença significativa entre os grupos, com exceção dos abandonos devido à falta de eficácia (grupo abatacepte apresentou resultados favoráveis em relação ao controle). O abatacepte possui maior eficácia quando comparado com o placebo, sem diferença significativa entre os grupos em termos de segurança.Unitermos: Abatacepte/eficácia. Artrite reumatóide. Metanálise.

show abstract

Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis

Cited by 89 publications

References 17 publications

Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis

Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About